Are you over 18 and want to see adult content?
More Annotations
A complete backup of ralphlauren.co.uk
Are you over 18 and want to see adult content?
A complete backup of amazingcarousel.com
Are you over 18 and want to see adult content?
A complete backup of stanstedairport.com
Are you over 18 and want to see adult content?
A complete backup of tipsbulletin.com
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of lexblogplatform.com
Are you over 18 and want to see adult content?
A complete backup of broadstreetreview.com
Are you over 18 and want to see adult content?
A complete backup of powertransmission.com
Are you over 18 and want to see adult content?
A complete backup of subversiones.org
Are you over 18 and want to see adult content?
A complete backup of victimconnect.org
Are you over 18 and want to see adult content?
A complete backup of studiopeertafels.nl
Are you over 18 and want to see adult content?
A complete backup of gardnermattress.com
Are you over 18 and want to see adult content?
A complete backup of laprensaparaguay.com
Are you over 18 and want to see adult content?
Text
patient care
ONCOLOGY PATIENTS
Your cancer is unique. Your treatment should be, too. At Tempus, we offer comprehensive genomic testing (DNA, RNA, etc). These next-generation sequencing tests can be performed to identify specific alterations that may drive the behavior of your cancer.ONCOLOGY - TEMPUS
How to order the Tempus sequencing test. We work directly with oncologists and pathologists to obtain normal and tumor samples. Once a physician and patient determine that Tempus testing is the right next step, the test can be ordered by the physician. Our kits include everything needed for specimen collection, including easy-to-follow CLINICAL TRIAL MATCHING THE TIME TRIAL® NETWORK Accessing the right clinical trial for the right patient at the right time. The TIME Trial Program is a just-in-time network of providers to support rapid patient identification, site activation, and enrollment of select clinicaltrials.
TEMPUS PATIENT ACCESS PROGRAM Tempus Patient Access Program | Financial Assistance TEMPUS TECH SPOTLIGHT THE TEMPUS HRD TEST from a variant assessment of 16 other HR-related genes (18 total) conducted as part of the xT testing. For breast, ovarian, and pancreatic samples, the Tempus HRD test TEMPUS - DATA-DRIVEN PRECISION MEDICINEPATIENTSCONTACT USAPPLICATIONSONCOLOGYNEUROLOGY & PSYCHIATRYRESEARCH Tempus is making precision medicine a reality through the power and promise of data and artificial intelligence. With the world’s largest library of clinical and molecular data, and an operating system to make that data accessible and useful, we enable physicians to make real-time, data-driven decisions to deliver personalizedpatient care
ONCOLOGY PATIENTS
Your cancer is unique. Your treatment should be, too. At Tempus, we offer comprehensive genomic testing (DNA, RNA, etc). These next-generation sequencing tests can be performed to identify specific alterations that may drive the behavior of your cancer.ONCOLOGY - TEMPUS
How to order the Tempus sequencing test. We work directly with oncologists and pathologists to obtain normal and tumor samples. Once a physician and patient determine that Tempus testing is the right next step, the test can be ordered by the physician. Our kits include everything needed for specimen collection, including easy-to-follow CLINICAL TRIAL MATCHING THE TIME TRIAL® NETWORK Accessing the right clinical trial for the right patient at the right time. The TIME Trial Program is a just-in-time network of providers to support rapid patient identification, site activation, and enrollment of select clinicaltrials.
TEMPUS PATIENT ACCESS PROGRAM Tempus Patient Access Program | Financial Assistance TEMPUS TECH SPOTLIGHT THE TEMPUS HRD TEST from a variant assessment of 16 other HR-related genes (18 total) conducted as part of the xT testing. For breast, ovarian, and pancreatic samples, the Tempus HRD testONCOLOGY PATIENTS
Your cancer is unique. Your treatment should be, too. At Tempus, we offer comprehensive genomic testing (DNA, RNA, etc). These next-generation sequencing tests can be performed to identify specific alterations that may drive the behavior of your cancer.ONCOLOGY - TEMPUS
How to order the Tempus sequencing test. We work directly with oncologists and pathologists to obtain normal and tumor samples. Once a physician and patient determine that Tempus testing is the right next step, the test can be ordered by the physician. Our kits include everything needed for specimen collection, including easy-to-follow TEMPUS AND YALE ANNOUNCE RESEARCH COLLABORATION TO Tempus, a leader in artificial intelligence and precision medicine, and the Yale School of Public Health announced a research collaboration to accelerate the development of COVID-19 diagnostic tests in the U.S. This partnership will leverage SalivaDirectTM, a saliva-based laboratory diagnostic test that has been developed by researchers at Yale. Tempus and Yale will further develop Continued TEMPUS UNVEILS TEMPUS XT, 595 GENE PANEL AIMED AT Tempus today announced the launch of its new comprehensive genomic sequencing panel, Tempus xT, which analyzes 595 genes relevant to the diagnosis, prognosis and therapeutic targeting of cancer. The panel will sequence a patient’s tumor DNA and RNA, as well as a matched normal blood or saliva to help ordering clinicians determine the targeted therapies Continued TEMPUS ANNOUNCES SEQUENCING AND COMPUTATIONAL BIOLOGY Tempus, a leader in artificial intelligence and precision medicine, today announced a collaboration with Kronos Bio, Inc., to perform sequencing analysis for patients enrolled in Kronos Bio’s Phase 1/2 clinical trial of KB-0742, the company’s investigational CDK9 inhibitor. Tempus will use its xT broad-panel genomic assay to provide retrospective sequencing and analytics for samplesPATTY SPILLER
Patty Spiller Patty serves as Senior Vice President of Marketing at Tempus, where she is responsible for the company’s Marketing and Communications strategy and functions. Prior to joining Tempus, Patty was Vice President of Growth Marketing at Livongo / Teladoc, a global leader in whole person virtual care. At Livongo, Patty founded and scaled the Continued TEMPUS EXPANDS LICENSING AGREEMENT WITH BRISTOL MYERS Tempus, a leader in artificial intelligence and precision medicine, today announced the expansion of an agreement with Bristol Myers Squibb, in which Tempus delivers de-identified transcriptomic datasets to enhance Bristol Myers Squibb’s research efforts on new biomarkers related to certain cancer subtypes. The agreement also enables rapid access to new datasets with standard TEMPUS TIME TRIAL™ PROGRAM REACHES CRITICAL SCALE AND Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, has reached a milestone in fully enrolling 2,500 oncologists into its Tempus Integrated Molecular Evaluation (TIME) Trial™ Program that seeks to rapidly match patients largely in the community setting to targeted clinical trials. To date, Tempus has signedMARC YOSKOWITZ
Marc Yoskowitz Marc Yoskowitz serves as EVP and Chief Strategy Officer, Life Sciences at Tempus. Prior to Tempus, Yoskowitz was Chief Business Officer, Pfizer Essential Health, leading a range of corporate initiatives and businesses within the Pfizer portfolio. Prior to Pfizer, he served as SVP, Strategy and Corporate Development at Hospira, where he led the Continued CVS HEALTH LAUNCHES TRANSFORM ONCOLOGY CARE™ PROGRAM TO CVS Health (NYSE: CVS) today announced Transform Oncology Care™, anchored on a first-of-its-kind precision medicine strategy for payors. The program uses genomic testing results at the point-of-prescribing to help patients start on the best treatment, faster and in addition, matches eligible patients to clinical trials. Transform Oncology Care also uses the Company’s local footprint and TEMPUS - DATA-DRIVEN PRECISION MEDICINEPATIENTSCONTACT USAPPLICATIONSONCOLOGYNEUROLOGY & PSYCHIATRYRESEARCH Tempus is making precision medicine a reality through the power and promise of data and artificial intelligence. With the world’s largest library of clinical and molecular data, and an operating system to make that data accessible and useful, we enable physicians to make real-time, data-driven decisions to deliver personalizedpatient care
ONCOLOGY PATIENTS
Your cancer is unique. Your treatment should be, too. At Tempus, we offer comprehensive genomic testing (DNA, RNA, etc). These next-generation sequencing tests can be performed to identify specific alterations that may drive the behavior of your cancer.ONCOLOGY - TEMPUS
How to order the Tempus sequencing test. We work directly with oncologists and pathologists to obtain normal and tumor samples. Once a physician and patient determine that Tempus testing is the right next step, the test can be ordered by the physician. Our kits include everything needed for specimen collection, including easy-to-follow TEMPUS PATIENT ACCESS PROGRAM Tempus Patient Access Program | Financial Assistance TEMPUS AND YALE ANNOUNCE RESEARCH COLLABORATION TO Tempus, a leader in artificial intelligence and precision medicine, and the Yale School of Public Health announced a research collaboration to accelerate the development of COVID-19 diagnostic tests in the U.S. This partnership will leverage SalivaDirectTM, a saliva-based laboratory diagnostic test that has been developed by researchers at Yale. Tempus and Yale will further develop Continued CLINICAL TRIAL MATCHING THE TIME TRIAL® NETWORK Accessing the right clinical trial for the right patient at the right time. The TIME Trial Program is a just-in-time network of providers to support rapid patient identification, site activation, and enrollment of select clinicaltrials.
TEMPUS EXPANDS LICENSING AGREEMENT WITH BRISTOL MYERS Tempus, a leader in artificial intelligence and precision medicine, today announced the expansion of an agreement with Bristol Myers Squibb, in which Tempus delivers de-identified transcriptomic datasets to enhance Bristol Myers Squibb’s research efforts on new biomarkers related to certain cancer subtypes. The agreement also enables rapid access to new datasets with standardSALIVADIRECT
SALIVADIRECT TM AT-HOME COLLECTION KIT Funnel Collection SALIVADIRE CT TM SALIVADIRECT TM IVD For Use Under Emergency Use Authorization (EUA) Only For individuals 18 years or older| REQUISITION FORM
Associated Study Study ID | REQUISITION FORM — 011221 Tempus Labs, Inc. | 600 West Chicago Avenue, Chicago, IL 60654 Phone: 800.739.4137| Fax: 800.893.0276
SUPPLEMENTAL INFORMATION IS REQUIRED FOR ALL ORDERS OF XG Tempus Labs, Inc. | 600 West Chicago Avenue, Chicago, IL 60654 | Phone: 800.739.4137 | Fax: 800.893.0276 | Tempus.com | support@tempus.com TEMPUS-FormXGSupp_031721 TEMPUS - DATA-DRIVEN PRECISION MEDICINEPATIENTSCONTACT USAPPLICATIONSONCOLOGYNEUROLOGY & PSYCHIATRYRESEARCH Tempus is making precision medicine a reality through the power and promise of data and artificial intelligence. With the world’s largest library of clinical and molecular data, and an operating system to make that data accessible and useful, we enable physicians to make real-time, data-driven decisions to deliver personalizedpatient care
ONCOLOGY PATIENTS
Your cancer is unique. Your treatment should be, too. At Tempus, we offer comprehensive genomic testing (DNA, RNA, etc). These next-generation sequencing tests can be performed to identify specific alterations that may drive the behavior of your cancer.ONCOLOGY - TEMPUS
How to order the Tempus sequencing test. We work directly with oncologists and pathologists to obtain normal and tumor samples. Once a physician and patient determine that Tempus testing is the right next step, the test can be ordered by the physician. Our kits include everything needed for specimen collection, including easy-to-follow TEMPUS PATIENT ACCESS PROGRAM Tempus Patient Access Program | Financial Assistance TEMPUS AND YALE ANNOUNCE RESEARCH COLLABORATION TO Tempus, a leader in artificial intelligence and precision medicine, and the Yale School of Public Health announced a research collaboration to accelerate the development of COVID-19 diagnostic tests in the U.S. This partnership will leverage SalivaDirectTM, a saliva-based laboratory diagnostic test that has been developed by researchers at Yale. Tempus and Yale will further develop Continued CLINICAL TRIAL MATCHING THE TIME TRIAL® NETWORK Accessing the right clinical trial for the right patient at the right time. The TIME Trial Program is a just-in-time network of providers to support rapid patient identification, site activation, and enrollment of select clinicaltrials.
TEMPUS EXPANDS LICENSING AGREEMENT WITH BRISTOL MYERS Tempus, a leader in artificial intelligence and precision medicine, today announced the expansion of an agreement with Bristol Myers Squibb, in which Tempus delivers de-identified transcriptomic datasets to enhance Bristol Myers Squibb’s research efforts on new biomarkers related to certain cancer subtypes. The agreement also enables rapid access to new datasets with standardSALIVADIRECT
SALIVADIRECT TM AT-HOME COLLECTION KIT Funnel Collection SALIVADIRE CT TM SALIVADIRECT TM IVD For Use Under Emergency Use Authorization (EUA) Only For individuals 18 years or older| REQUISITION FORM
Associated Study Study ID | REQUISITION FORM — 011221 Tempus Labs, Inc. | 600 West Chicago Avenue, Chicago, IL 60654 Phone: 800.739.4137| Fax: 800.893.0276
SUPPLEMENTAL INFORMATION IS REQUIRED FOR ALL ORDERS OF XG Tempus Labs, Inc. | 600 West Chicago Avenue, Chicago, IL 60654 | Phone: 800.739.4137 | Fax: 800.893.0276 | Tempus.com | support@tempus.com TEMPUS-FormXGSupp_031721ONCOLOGY - TEMPUS
How to order the Tempus sequencing test. We work directly with oncologists and pathologists to obtain normal and tumor samples. Once a physician and patient determine that Tempus testing is the right next step, the test can be ordered by the physician. Our kits include everything needed for specimen collection, including easy-to-followOUR TEAM - TEMPUS
We are a team with a singular shared goal: to improve patient outcomes. We are the collective of our combined knowledge base. Our team has a breadth of expertise, and together, we attack cancer from every direction. "If you want to go fast, go alone; if you want to go far, go together." Join our team. TEMPUS AND YALE ANNOUNCE RESEARCH COLLABORATION TO Tempus, a leader in artificial intelligence and precision medicine, and the Yale School of Public Health announced a research collaboration to accelerate the development of COVID-19 diagnostic tests in the U.S. This partnership will leverage SalivaDirectTM, a saliva-based laboratory diagnostic test that has been developed by researchers at Yale. Tempus and Yale will further develop ContinuedCAREERS - TEMPUS
Histotechnologist (Tuesday - Saturday, Mid Shift) Lab Assistant for Histology (Sunday - Thursday, 7:00-3:30pm Shift) Lab Assistant for Histology (Tuesday - Saturday, Midshift) Lab Operations Associate. Lab Operations Associate (Tuesday - Saturday, Midshift) Lab OperationsProject Manager.
TEMPUS TECH SPOTLIGHT THE TEMPUS HRD TEST from a variant assessment of 16 other HR-related genes (18 total) conducted as part of the xT testing. For breast, ovarian, and pancreatic samples, the Tempus HRD test TEMPUS UNVEILS TEMPUS XT, 595 GENE PANEL AIMED AT Tempus today announced the launch of its new comprehensive genomic sequencing panel, Tempus xT, which analyzes 595 genes relevant to the diagnosis, prognosis and therapeutic targeting of cancer. The panel will sequence a patient’s tumor DNA and RNA, as well as a matched normal blood or saliva to help ordering clinicians determine the targeted therapies Continued TEMPUS ANNOUNCES SEQUENCING AND COMPUTATIONAL BIOLOGY Tempus, a leader in artificial intelligence and precision medicine, today announced a collaboration with Kronos Bio, Inc., to perform sequencing analysis for patients enrolled in Kronos Bio’s Phase 1/2 clinical trial of KB-0742, the company’s investigational CDK9 inhibitor. Tempus will use its xT broad-panel genomic assay to provide retrospective sequencing and analytics for samples REAL-WORLD EVIDENCE OF DIAGNOSTIC TESTING AND TREATMENT Clinical Breast Cancer, Tempus-authored — Objective/Background We performed a retrospective analysis of longitudinal real-world data (RWD) from patients with breast cancer to replicate results from clinical studies and demonstrate the feasibility of generating real-world evidence. We also assessed the value of transcriptome profiling as a complementary tool for determining molecular THIS GUIDE IS DESIGNED TO HELP YOU COMPLETE THE TEMPUS I Phenotypic Attributes and Clinical Information (see below for details) Please include a clinical history or progress notes and pathology report, or complete this section CVS HEALTH LAUNCHES TRANSFORM ONCOLOGY CARE™ PROGRAM TO CVS Health (NYSE: CVS) today announced Transform Oncology Care™, anchored on a first-of-its-kind precision medicine strategy for payors. The program uses genomic testing results at the point-of-prescribing to help patients start on the best treatment, faster and in addition, matches eligible patients to clinical trials. Transform Oncology Care also uses the Company’s local footprint and TEMPUS - DATA-DRIVEN PRECISION MEDICINEPATIENTSCONTACT USAPPLICATIONSONCOLOGYNEUROLOGY & PSYCHIATRYRESEARCH Data-driven precision medicine. Tempus is making precision medicine a reality through the power and promise of data and artificial intelligence. With the world’s largest library of clinical and molecular data, and an operating system to make that data accessible and useful, we enable physicians to make real-time, data-driven decisions to deliver personalized patient care, and in parallelONCOLOGY PATIENTS
Your cancer is unique. Your treatment should be, too. At Tempus, we offer comprehensive genomic testing (DNA, RNA, etc). These next-generation sequencing tests can be performed to identify specific alterations that may drive the behavior of your cancer.ONCOLOGY - TEMPUS
ONCOLOGY. Through our smart genomic profiling tests and targeted clinical trial matching, Tempus informs treatment options for your patients at every point CLINICAL TRIAL MATCHING THE TIME TRIAL® NETWORK Accessing the right clinical trial for the right patient at the right time. The TIME Trial Program is a just-in-time network of providers to support rapid patient identification, site activation, and enrollment of select clinicaltrials.
TEMPUS PATIENT ACCESS PROGRAM Tempus Patient Access Program | Financial Assistance TEMPUS TECH SPOTLIGHT THE TEMPUS HRD TEST from a variant assessment of 16 other HR-related genes (18 total) conducted as part of the xT testing. For breast, ovarian, and pancreatic samples, the Tempus HRD testSALIVADIRECT
SALIVADIRECT TM AT-HOME COLLECTION KIT Funnel Collection SALIVADIRE CT TM SALIVADIRECT TM IVD For Use Under Emergency Use Authorization (EUA) Only For individuals 18 years or older REAL-WORLD EVIDENCE OF DIAGNOSTIC TESTING AND TREATMENT Clinical Breast Cancer, Tempus-authored — Objective/Background We performed a retrospective analysis of longitudinal real-world data (RWD) from patients with breast cancer to replicate results from clinical studies and demonstrate the feasibility of generating real-world evidence. We also assessed the value of transcriptome profiling as a complementary tool for determining molecular TEMPUS EXPANDS LICENSING AGREEMENT WITH BRISTOL MYERS Tempus, a leader in artificial intelligence and precision medicine, today announced the expansion of an agreement with Bristol Myers Squibb, in which Tempus delivers de-identified transcriptomic datasets to enhance Bristol Myers Squibb’s research efforts on new biomarkers related to certain cancer subtypes. The agreement also enables rapid access to new datasets with standard SUPPLEMENTAL INFORMATION IS REQUIRED FOR ALL ORDERS OF XG Tempus Labs, Inc. | 600 West Chicago Avenue, Chicago, IL 60654 | Phone: 800.739.4137 | Fax: 800.893.0276 | Tempus.com | support@tempus.com TEMPUS-FormXGSupp_031721 TEMPUS - DATA-DRIVEN PRECISION MEDICINEPATIENTSCONTACT USAPPLICATIONSONCOLOGYNEUROLOGY & PSYCHIATRYRESEARCH Data-driven precision medicine. Tempus is making precision medicine a reality through the power and promise of data and artificial intelligence. With the world’s largest library of clinical and molecular data, and an operating system to make that data accessible and useful, we enable physicians to make real-time, data-driven decisions to deliver personalized patient care, and in parallelONCOLOGY PATIENTS
Your cancer is unique. Your treatment should be, too. At Tempus, we offer comprehensive genomic testing (DNA, RNA, etc). These next-generation sequencing tests can be performed to identify specific alterations that may drive the behavior of your cancer.ONCOLOGY - TEMPUS
ONCOLOGY. Through our smart genomic profiling tests and targeted clinical trial matching, Tempus informs treatment options for your patients at every point CLINICAL TRIAL MATCHING THE TIME TRIAL® NETWORK Accessing the right clinical trial for the right patient at the right time. The TIME Trial Program is a just-in-time network of providers to support rapid patient identification, site activation, and enrollment of select clinicaltrials.
TEMPUS PATIENT ACCESS PROGRAM Tempus Patient Access Program | Financial Assistance TEMPUS TECH SPOTLIGHT THE TEMPUS HRD TEST from a variant assessment of 16 other HR-related genes (18 total) conducted as part of the xT testing. For breast, ovarian, and pancreatic samples, the Tempus HRD testSALIVADIRECT
SALIVADIRECT TM AT-HOME COLLECTION KIT Funnel Collection SALIVADIRE CT TM SALIVADIRECT TM IVD For Use Under Emergency Use Authorization (EUA) Only For individuals 18 years or older REAL-WORLD EVIDENCE OF DIAGNOSTIC TESTING AND TREATMENT Clinical Breast Cancer, Tempus-authored — Objective/Background We performed a retrospective analysis of longitudinal real-world data (RWD) from patients with breast cancer to replicate results from clinical studies and demonstrate the feasibility of generating real-world evidence. We also assessed the value of transcriptome profiling as a complementary tool for determining molecular TEMPUS EXPANDS LICENSING AGREEMENT WITH BRISTOL MYERS Tempus, a leader in artificial intelligence and precision medicine, today announced the expansion of an agreement with Bristol Myers Squibb, in which Tempus delivers de-identified transcriptomic datasets to enhance Bristol Myers Squibb’s research efforts on new biomarkers related to certain cancer subtypes. The agreement also enables rapid access to new datasets with standard SUPPLEMENTAL INFORMATION IS REQUIRED FOR ALL ORDERS OF XG Tempus Labs, Inc. | 600 West Chicago Avenue, Chicago, IL 60654 | Phone: 800.739.4137 | Fax: 800.893.0276 | Tempus.com | support@tempus.com TEMPUS-FormXGSupp_031721 TEMPUS AND YALE ANNOUNCE RESEARCH COLLABORATION TO Tempus, a leader in artificial intelligence and precision medicine, and the Yale School of Public Health announced a research collaboration to accelerate the development of COVID-19 diagnostic tests in the U.S. This partnership will leverage SalivaDirectTM, a saliva-based laboratory diagnostic test that has been developed by researchers at Yale. Tempus and Yale will further develop Continued TEMPUS UNVEILS TEMPUS XT, 595 GENE PANEL AIMED AT Tempus today announced the launch of its new comprehensive genomic sequencing panel, Tempus xT, which analyzes 595 genes relevant to the diagnosis, prognosis and therapeutic targeting of cancer. The panel will sequence a patient’s tumor DNA and RNA, as well as a matched normal blood or saliva to help ordering clinicians determine the targeted therapies Continued TEMPUS TECH SPOTLIGHT THE TEMPUS HRD TEST from a variant assessment of 16 other HR-related genes (18 total) conducted as part of the xT testing. For breast, ovarian, and pancreatic samples, the Tempus HRD test TEMPUS ANNOUNCES SEQUENCING AND COMPUTATIONAL BIOLOGY Tempus, a leader in artificial intelligence and precision medicine, today announced a collaboration with Kronos Bio, Inc., to perform sequencing analysis for patients enrolled in Kronos Bio’s Phase 1/2 clinical trial of KB-0742, the company’s investigational CDK9 inhibitor. Tempus will use its xT broad-panel genomic assay to provide retrospective sequencing and analytics for samplesPATTY SPILLER
Patty Spiller Patty serves as Senior Vice President of Marketing at Tempus, where she is responsible for the company’s Marketing and Communications strategy and functions. Prior to joining Tempus, Patty was Vice President of Growth Marketing at Livongo / Teladoc, a global leader in whole person virtual care. At Livongo, Patty founded and scaled the Continued TEMPUS EXPANDS LICENSING AGREEMENT WITH BRISTOL MYERS Tempus, a leader in artificial intelligence and precision medicine, today announced the expansion of an agreement with Bristol Myers Squibb, in which Tempus delivers de-identified transcriptomic datasets to enhance Bristol Myers Squibb’s research efforts on new biomarkers related to certain cancer subtypes. The agreement also enables rapid access to new datasets with standard TEMPUS TIME TRIAL™ PROGRAM REACHES CRITICAL SCALE AND Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, has reached a milestone in fully enrolling 2,500 oncologists into its Tempus Integrated Molecular Evaluation (TIME) Trial™ Program that seeks to rapidly match patients largely in the community setting to targeted clinical trials. To date, Tempus has signedMARC YOSKOWITZ
Marc Yoskowitz Marc Yoskowitz serves as EVP and Chief Strategy Officer, Life Sciences at Tempus. Prior to Tempus, Yoskowitz was Chief Business Officer, Pfizer Essential Health, leading a range of corporate initiatives and businesses within the Pfizer portfolio. Prior to Pfizer, he served as SVP, Strategy and Corporate Development at Hospira, where he led the Continued THIS GUIDE IS DESIGNED TO HELP YOU COMPLETE THE TEMPUS I Phenotypic Attributes and Clinical Information (see below for details) Please include a clinical history or progress notes and pathology report, or complete this section CVS HEALTH LAUNCHES TRANSFORM ONCOLOGY CARE™ PROGRAM TO CVS Health (NYSE: CVS) today announced Transform Oncology Care™, anchored on a first-of-its-kind precision medicine strategy for payors. The program uses genomic testing results at the point-of-prescribing to help patients start on the best treatment, faster and in addition, matches eligible patients to clinical trials. Transform Oncology Care also uses the Company’s local footprint and TEMPUS - DATA-DRIVEN PRECISION MEDICINEPATIENTSCONTACT USAPPLICATIONSONCOLOGYNEUROLOGY & PSYCHIATRYRESEARCH Tempus is making precision medicine a reality through the power and promise of data and artificial intelligence. With the world’s largest library of clinical and molecular data, and an operating system to make that data accessible and useful, we enable physicians to make real-time, data-driven decisions to deliver personalizedpatient care
ONCOLOGY PATIENTS
Your cancer is unique. Your treatment should be, too. At Tempus, we offer comprehensive genomic testing (DNA, RNA, etc). These next-generation sequencing tests can be performed to identify specific alterations that may drive the behavior of your cancer.ONCOLOGY - TEMPUS
How to order the Tempus sequencing test. We work directly with oncologists and pathologists to obtain normal and tumor samples. Once a physician and patient determine that Tempus testing is the right next step, the test can be ordered by the physician. Our kits include everything needed for specimen collection, including easy-to-follow TEMPUS PATIENT ACCESS PROGRAM Tempus Patient Access Program | Financial Assistance TEMPUS AND YALE ANNOUNCE RESEARCH COLLABORATION TO Tempus, a leader in artificial intelligence and precision medicine, and the Yale School of Public Health announced a research collaboration to accelerate the development of COVID-19 diagnostic tests in the U.S. This partnership will leverage SalivaDirectTM, a saliva-based laboratory diagnostic test that has been developed by researchers at Yale. Tempus and Yale will further develop Continued CLINICAL TRIAL MATCHING THE TIME TRIAL® NETWORK Accessing the right clinical trial for the right patient at the right time. The TIME Trial Program is a just-in-time network of providers to support rapid patient identification, site activation, and enrollment of select clinicaltrials.
REAL-WORLD EVIDENCE OF DIAGNOSTIC TESTING AND TREATMENT Clinical Breast Cancer, Tempus-authored — Objective/Background We performed a retrospective analysis of longitudinal real-world data (RWD) from patients with breast cancer to replicate results from clinical studies and demonstrate the feasibility of generating real-world evidence. We also assessed the value of transcriptome profiling as a complementary tool for determining molecularSALIVADIRECT
SALIVADIRECT TM AT-HOME COLLECTION KIT Funnel Collection SALIVADIRE CT TM SALIVADIRECT TM IVD For Use Under Emergency Use Authorization (EUA) Only For individuals 18 years or older THIS GUIDE IS DESIGNED TO HELP YOU COMPLETE THE TEMPUS I Phenotypic Attributes and Clinical Information (see below for details) Please include a clinical history or progress notes and pathology report, or complete this section SUPPLEMENTAL INFORMATION IS REQUIRED FOR ALL ORDERS OF XG Tempus Labs, Inc. | 600 West Chicago Avenue, Chicago, IL 60654 | Phone: 800.739.4137 | Fax: 800.893.0276 | Tempus.com | support@tempus.com TEMPUS-FormXGSupp_031721 TEMPUS - DATA-DRIVEN PRECISION MEDICINEPATIENTSCONTACT USAPPLICATIONSONCOLOGYNEUROLOGY & PSYCHIATRYRESEARCH Tempus is making precision medicine a reality through the power and promise of data and artificial intelligence. With the world’s largest library of clinical and molecular data, and an operating system to make that data accessible and useful, we enable physicians to make real-time, data-driven decisions to deliver personalizedpatient care
ONCOLOGY PATIENTS
Your cancer is unique. Your treatment should be, too. At Tempus, we offer comprehensive genomic testing (DNA, RNA, etc). These next-generation sequencing tests can be performed to identify specific alterations that may drive the behavior of your cancer.ONCOLOGY - TEMPUS
How to order the Tempus sequencing test. We work directly with oncologists and pathologists to obtain normal and tumor samples. Once a physician and patient determine that Tempus testing is the right next step, the test can be ordered by the physician. Our kits include everything needed for specimen collection, including easy-to-follow TEMPUS PATIENT ACCESS PROGRAM Tempus Patient Access Program | Financial Assistance TEMPUS AND YALE ANNOUNCE RESEARCH COLLABORATION TO Tempus, a leader in artificial intelligence and precision medicine, and the Yale School of Public Health announced a research collaboration to accelerate the development of COVID-19 diagnostic tests in the U.S. This partnership will leverage SalivaDirectTM, a saliva-based laboratory diagnostic test that has been developed by researchers at Yale. Tempus and Yale will further develop Continued CLINICAL TRIAL MATCHING THE TIME TRIAL® NETWORK Accessing the right clinical trial for the right patient at the right time. The TIME Trial Program is a just-in-time network of providers to support rapid patient identification, site activation, and enrollment of select clinicaltrials.
REAL-WORLD EVIDENCE OF DIAGNOSTIC TESTING AND TREATMENT Clinical Breast Cancer, Tempus-authored — Objective/Background We performed a retrospective analysis of longitudinal real-world data (RWD) from patients with breast cancer to replicate results from clinical studies and demonstrate the feasibility of generating real-world evidence. We also assessed the value of transcriptome profiling as a complementary tool for determining molecularSALIVADIRECT
SALIVADIRECT TM AT-HOME COLLECTION KIT Funnel Collection SALIVADIRE CT TM SALIVADIRECT TM IVD For Use Under Emergency Use Authorization (EUA) Only For individuals 18 years or older THIS GUIDE IS DESIGNED TO HELP YOU COMPLETE THE TEMPUS I Phenotypic Attributes and Clinical Information (see below for details) Please include a clinical history or progress notes and pathology report, or complete this section SUPPLEMENTAL INFORMATION IS REQUIRED FOR ALL ORDERS OF XG Tempus Labs, Inc. | 600 West Chicago Avenue, Chicago, IL 60654 | Phone: 800.739.4137 | Fax: 800.893.0276 | Tempus.com | support@tempus.com TEMPUS-FormXGSupp_031721ONCOLOGY - TEMPUS
How to order the Tempus sequencing test. We work directly with oncologists and pathologists to obtain normal and tumor samples. Once a physician and patient determine that Tempus testing is the right next step, the test can be ordered by the physician. Our kits include everything needed for specimen collection, including easy-to-followCOVID-19 FAQ
For patients with health insurance, Tempus bills insurers $120 for the test. Most insurers have waived patient responsibility and copays for COVID-19 diagnostic testing. For those without insurance, testing is available and covered as part of the U.S. COVID-19 Uninsured Program. More information on this program can be found here.OUR TEAM - TEMPUS
We are a team with a singular shared goal: to improve patient outcomes. We are the collective of our combined knowledge base. Our team has a breadth of expertise, and together, we attack cancer from every direction. "If you want to go fast, go alone; if you want to go far, go together." Join our team. TEMPUS AND YALE ANNOUNCE RESEARCH COLLABORATION TO Tempus, a leader in artificial intelligence and precision medicine, and the Yale School of Public Health announced a research collaboration to accelerate the development of COVID-19 diagnostic tests in the U.S. This partnership will leverage SalivaDirectTM, a saliva-based laboratory diagnostic test that has been developed by researchers at Yale. Tempus and Yale will further develop Continued TEMPUS UNVEILS TEMPUS XT, 595 GENE PANEL AIMED AT Tempus today announced the launch of its new comprehensive genomic sequencing panel, Tempus xT, which analyzes 595 genes relevant to the diagnosis, prognosis and therapeutic targeting of cancer. The panel will sequence a patient’s tumor DNA and RNA, as well as a matched normal blood or saliva to help ordering clinicians determine the targeted therapies Continued TEMPUS ANNOUNCES SEQUENCING AND COMPUTATIONAL BIOLOGY Tempus, a leader in artificial intelligence and precision medicine, today announced a collaboration with Kronos Bio, Inc., to perform sequencing analysis for patients enrolled in Kronos Bio’s Phase 1/2 clinical trial of KB-0742, the company’s investigational CDK9 inhibitor. Tempus will use its xT broad-panel genomic assay to provide retrospective sequencing and analytics for samples TEMPUS TECH SPOTLIGHT THE TEMPUS HRD TEST from a variant assessment of 16 other HR-related genes (18 total) conducted as part of the xT testing. For breast, ovarian, and pancreatic samples, the Tempus HRD test REAL-WORLD EVIDENCE OF DIAGNOSTIC TESTING AND TREATMENT Clinical Breast Cancer, Tempus-authored — Objective/Background We performed a retrospective analysis of longitudinal real-world data (RWD) from patients with breast cancer to replicate results from clinical studies and demonstrate the feasibility of generating real-world evidence. We also assessed the value of transcriptome profiling as a complementary tool for determining molecular THIS GUIDE IS DESIGNED TO HELP YOU COMPLETE THE TEMPUS I Phenotypic Attributes and Clinical Information (see below for details) Please include a clinical history or progress notes and pathology report, or complete this section CVS HEALTH LAUNCHES TRANSFORM ONCOLOGY CARE™ PROGRAM TO CVS Health (NYSE: CVS) today announced Transform Oncology Care™, anchored on a first-of-its-kind precision medicine strategy for payors. The program uses genomic testing results at the point-of-prescribing to help patients start on the best treatment, faster and in addition, matches eligible patients to clinical trials. Transform Oncology Care also uses the Company’s local footprint and TEMPUS - DATA-DRIVEN PRECISION MEDICINEPATIENTSCONTACT USAPPLICATIONSONCOLOGYNEUROLOGY & PSYCHIATRYRESEARCH Tempus is making precision medicine a reality through the power and promise of data and artificial intelligence. With the world’s largest library of clinical and molecular data, and an operating system to make that data accessible and useful, we enable physicians to make real-time, data-driven decisions to deliver personalizedpatient care
ONCOLOGY PATIENTS
Your cancer is unique. Your treatment should be, too. At Tempus, we offer comprehensive genomic testing (DNA, RNA, etc). These next-generation sequencing tests can be performed to identify specific alterations that may drive the behavior of your cancer.ONCOLOGY - TEMPUS
How to order the Tempus sequencing test. We work directly with oncologists and pathologists to obtain normal and tumor samples. Once a physician and patient determine that Tempus testing is the right next step, the test can be ordered by the physician. Our kits include everything needed for specimen collection, including easy-to-follow TEMPUS PATIENT ACCESS PROGRAM Tempus Patient Access Program | Financial Assistance TEMPUS AND YALE ANNOUNCE RESEARCH COLLABORATION TO Tempus, a leader in artificial intelligence and precision medicine, and the Yale School of Public Health announced a research collaboration to accelerate the development of COVID-19 diagnostic tests in the U.S. This partnership will leverage SalivaDirectTM, a saliva-based laboratory diagnostic test that has been developed by researchers at Yale. Tempus and Yale will further develop Continued CLINICAL TRIAL MATCHING THE TIME TRIAL® NETWORK Accessing the right clinical trial for the right patient at the right time. The TIME Trial Program is a just-in-time network of providers to support rapid patient identification, site activation, and enrollment of select clinicaltrials.
REAL-WORLD EVIDENCE OF DIAGNOSTIC TESTING AND TREATMENT Clinical Breast Cancer, Tempus-authored — Objective/Background We performed a retrospective analysis of longitudinal real-world data (RWD) from patients with breast cancer to replicate results from clinical studies and demonstrate the feasibility of generating real-world evidence. We also assessed the value of transcriptome profiling as a complementary tool for determining molecularSALIVADIRECT
SALIVADIRECT TM AT-HOME COLLECTION KIT Funnel Collection SALIVADIRE CT TM SALIVADIRECT TM IVD For Use Under Emergency Use Authorization (EUA) Only For individuals 18 years or older THIS GUIDE IS DESIGNED TO HELP YOU COMPLETE THE TEMPUS I Phenotypic Attributes and Clinical Information (see below for details) Please include a clinical history or progress notes and pathology report, or complete this section SUPPLEMENTAL INFORMATION IS REQUIRED FOR ALL ORDERS OF XG Tempus Labs, Inc. | 600 West Chicago Avenue, Chicago, IL 60654 | Phone: 800.739.4137 | Fax: 800.893.0276 | Tempus.com | support@tempus.com TEMPUS-FormXGSupp_031721 TEMPUS - DATA-DRIVEN PRECISION MEDICINEPATIENTSCONTACT USAPPLICATIONSONCOLOGYNEUROLOGY & PSYCHIATRYRESEARCH Tempus is making precision medicine a reality through the power and promise of data and artificial intelligence. With the world’s largest library of clinical and molecular data, and an operating system to make that data accessible and useful, we enable physicians to make real-time, data-driven decisions to deliver personalizedpatient care
ONCOLOGY PATIENTS
Your cancer is unique. Your treatment should be, too. At Tempus, we offer comprehensive genomic testing (DNA, RNA, etc). These next-generation sequencing tests can be performed to identify specific alterations that may drive the behavior of your cancer.ONCOLOGY - TEMPUS
How to order the Tempus sequencing test. We work directly with oncologists and pathologists to obtain normal and tumor samples. Once a physician and patient determine that Tempus testing is the right next step, the test can be ordered by the physician. Our kits include everything needed for specimen collection, including easy-to-follow TEMPUS PATIENT ACCESS PROGRAM Tempus Patient Access Program | Financial Assistance TEMPUS AND YALE ANNOUNCE RESEARCH COLLABORATION TO Tempus, a leader in artificial intelligence and precision medicine, and the Yale School of Public Health announced a research collaboration to accelerate the development of COVID-19 diagnostic tests in the U.S. This partnership will leverage SalivaDirectTM, a saliva-based laboratory diagnostic test that has been developed by researchers at Yale. Tempus and Yale will further develop Continued CLINICAL TRIAL MATCHING THE TIME TRIAL® NETWORK Accessing the right clinical trial for the right patient at the right time. The TIME Trial Program is a just-in-time network of providers to support rapid patient identification, site activation, and enrollment of select clinicaltrials.
REAL-WORLD EVIDENCE OF DIAGNOSTIC TESTING AND TREATMENT Clinical Breast Cancer, Tempus-authored — Objective/Background We performed a retrospective analysis of longitudinal real-world data (RWD) from patients with breast cancer to replicate results from clinical studies and demonstrate the feasibility of generating real-world evidence. We also assessed the value of transcriptome profiling as a complementary tool for determining molecularSALIVADIRECT
SALIVADIRECT TM AT-HOME COLLECTION KIT Funnel Collection SALIVADIRE CT TM SALIVADIRECT TM IVD For Use Under Emergency Use Authorization (EUA) Only For individuals 18 years or older THIS GUIDE IS DESIGNED TO HELP YOU COMPLETE THE TEMPUS I Phenotypic Attributes and Clinical Information (see below for details) Please include a clinical history or progress notes and pathology report, or complete this section SUPPLEMENTAL INFORMATION IS REQUIRED FOR ALL ORDERS OF XG Tempus Labs, Inc. | 600 West Chicago Avenue, Chicago, IL 60654 | Phone: 800.739.4137 | Fax: 800.893.0276 | Tempus.com | support@tempus.com TEMPUS-FormXGSupp_031721ONCOLOGY - TEMPUS
How to order the Tempus sequencing test. We work directly with oncologists and pathologists to obtain normal and tumor samples. Once a physician and patient determine that Tempus testing is the right next step, the test can be ordered by the physician. Our kits include everything needed for specimen collection, including easy-to-followCOVID-19 FAQ
For patients with health insurance, Tempus bills insurers $120 for the test. Most insurers have waived patient responsibility and copays for COVID-19 diagnostic testing. For those without insurance, testing is available and covered as part of the U.S. COVID-19 Uninsured Program. More information on this program can be found here.OUR TEAM - TEMPUS
We are a team with a singular shared goal: to improve patient outcomes. We are the collective of our combined knowledge base. Our team has a breadth of expertise, and together, we attack cancer from every direction. "If you want to go fast, go alone; if you want to go far, go together." Join our team. TEMPUS AND YALE ANNOUNCE RESEARCH COLLABORATION TO Tempus, a leader in artificial intelligence and precision medicine, and the Yale School of Public Health announced a research collaboration to accelerate the development of COVID-19 diagnostic tests in the U.S. This partnership will leverage SalivaDirectTM, a saliva-based laboratory diagnostic test that has been developed by researchers at Yale. Tempus and Yale will further develop Continued TEMPUS UNVEILS TEMPUS XT, 595 GENE PANEL AIMED AT Tempus today announced the launch of its new comprehensive genomic sequencing panel, Tempus xT, which analyzes 595 genes relevant to the diagnosis, prognosis and therapeutic targeting of cancer. The panel will sequence a patient’s tumor DNA and RNA, as well as a matched normal blood or saliva to help ordering clinicians determine the targeted therapies Continued TEMPUS ANNOUNCES SEQUENCING AND COMPUTATIONAL BIOLOGY Tempus, a leader in artificial intelligence and precision medicine, today announced a collaboration with Kronos Bio, Inc., to perform sequencing analysis for patients enrolled in Kronos Bio’s Phase 1/2 clinical trial of KB-0742, the company’s investigational CDK9 inhibitor. Tempus will use its xT broad-panel genomic assay to provide retrospective sequencing and analytics for samples TEMPUS TECH SPOTLIGHT THE TEMPUS HRD TEST from a variant assessment of 16 other HR-related genes (18 total) conducted as part of the xT testing. For breast, ovarian, and pancreatic samples, the Tempus HRD test REAL-WORLD EVIDENCE OF DIAGNOSTIC TESTING AND TREATMENT Clinical Breast Cancer, Tempus-authored — Objective/Background We performed a retrospective analysis of longitudinal real-world data (RWD) from patients with breast cancer to replicate results from clinical studies and demonstrate the feasibility of generating real-world evidence. We also assessed the value of transcriptome profiling as a complementary tool for determining molecular THIS GUIDE IS DESIGNED TO HELP YOU COMPLETE THE TEMPUS I Phenotypic Attributes and Clinical Information (see below for details) Please include a clinical history or progress notes and pathology report, or complete this section CVS HEALTH LAUNCHES TRANSFORM ONCOLOGY CARE™ PROGRAM TO CVS Health (NYSE: CVS) today announced Transform Oncology Care™, anchored on a first-of-its-kind precision medicine strategy for payors. The program uses genomic testing results at the point-of-prescribing to help patients start on the best treatment, faster and in addition, matches eligible patients to clinical trials. Transform Oncology Care also uses the Company’s local footprint and TEMPUS - DATA-DRIVEN PRECISION MEDICINEPATIENTSCONTACT USAPPLICATIONSONCOLOGYNEUROLOGY & PSYCHIATRYRESEARCH Tempus is making precision medicine a reality through the power and promise of data and artificial intelligence. With the world’s largest library of clinical and molecular data, and an operating system to make that data accessible and useful, we enable physicians to make real-time, data-driven decisions to deliver personalizedpatient care
ONCOLOGY PATIENTS
Your cancer is unique. Your treatment should be, too. At Tempus, we offer comprehensive genomic testing (DNA, RNA, etc). These next-generation sequencing tests can be performed to identify specific alterations that may drive the behavior of your cancer.ONCOLOGY - TEMPUS
How to order the Tempus sequencing test. We work directly with oncologists and pathologists to obtain normal and tumor samples. Once a physician and patient determine that Tempus testing is the right next step, the test can be ordered by the physician. Our kits include everything needed for specimen collection, including easy-to-follow TEMPUS PATIENT ACCESS PROGRAM Tempus Patient Access Program | Financial Assistance TEMPUS AND YALE ANNOUNCE RESEARCH COLLABORATION TO Tempus, a leader in artificial intelligence and precision medicine, and the Yale School of Public Health announced a research collaboration to accelerate the development of COVID-19 diagnostic tests in the U.S. This partnership will leverage SalivaDirectTM, a saliva-based laboratory diagnostic test that has been developed by researchers at Yale. Tempus and Yale will further develop Continued CLINICAL TRIAL MATCHING THE TIME TRIAL® NETWORK Accessing the right clinical trial for the right patient at the right time. The TIME Trial Program is a just-in-time network of providers to support rapid patient identification, site activation, and enrollment of select clinicaltrials.
REAL-WORLD EVIDENCE OF DIAGNOSTIC TESTING AND TREATMENT Clinical Breast Cancer, Tempus-authored — Objective/Background We performed a retrospective analysis of longitudinal real-world data (RWD) from patients with breast cancer to replicate results from clinical studies and demonstrate the feasibility of generating real-world evidence. We also assessed the value of transcriptome profiling as a complementary tool for determining molecularSALIVADIRECT
SALIVADIRECT TM AT-HOME COLLECTION KIT Funnel Collection SALIVADIRE CT TM SALIVADIRECT TM IVD For Use Under Emergency Use Authorization (EUA) Only For individuals 18 years or older THIS GUIDE IS DESIGNED TO HELP YOU COMPLETE THE TEMPUS I Phenotypic Attributes and Clinical Information (see below for details) Please include a clinical history or progress notes and pathology report, or complete this section SUPPLEMENTAL INFORMATION IS REQUIRED FOR ALL ORDERS OF XG Tempus Labs, Inc. | 600 West Chicago Avenue, Chicago, IL 60654 | Phone: 800.739.4137 | Fax: 800.893.0276 | Tempus.com | support@tempus.com TEMPUS-FormXGSupp_031721 TEMPUS - DATA-DRIVEN PRECISION MEDICINEPATIENTSCONTACT USAPPLICATIONSONCOLOGYNEUROLOGY & PSYCHIATRYRESEARCH Tempus is making precision medicine a reality through the power and promise of data and artificial intelligence. With the world’s largest library of clinical and molecular data, and an operating system to make that data accessible and useful, we enable physicians to make real-time, data-driven decisions to deliver personalizedpatient care
ONCOLOGY PATIENTS
Your cancer is unique. Your treatment should be, too. At Tempus, we offer comprehensive genomic testing (DNA, RNA, etc). These next-generation sequencing tests can be performed to identify specific alterations that may drive the behavior of your cancer.ONCOLOGY - TEMPUS
How to order the Tempus sequencing test. We work directly with oncologists and pathologists to obtain normal and tumor samples. Once a physician and patient determine that Tempus testing is the right next step, the test can be ordered by the physician. Our kits include everything needed for specimen collection, including easy-to-follow TEMPUS PATIENT ACCESS PROGRAM Tempus Patient Access Program | Financial Assistance TEMPUS AND YALE ANNOUNCE RESEARCH COLLABORATION TO Tempus, a leader in artificial intelligence and precision medicine, and the Yale School of Public Health announced a research collaboration to accelerate the development of COVID-19 diagnostic tests in the U.S. This partnership will leverage SalivaDirectTM, a saliva-based laboratory diagnostic test that has been developed by researchers at Yale. Tempus and Yale will further develop Continued CLINICAL TRIAL MATCHING THE TIME TRIAL® NETWORK Accessing the right clinical trial for the right patient at the right time. The TIME Trial Program is a just-in-time network of providers to support rapid patient identification, site activation, and enrollment of select clinicaltrials.
REAL-WORLD EVIDENCE OF DIAGNOSTIC TESTING AND TREATMENT Clinical Breast Cancer, Tempus-authored — Objective/Background We performed a retrospective analysis of longitudinal real-world data (RWD) from patients with breast cancer to replicate results from clinical studies and demonstrate the feasibility of generating real-world evidence. We also assessed the value of transcriptome profiling as a complementary tool for determining molecularSALIVADIRECT
SALIVADIRECT TM AT-HOME COLLECTION KIT Funnel Collection SALIVADIRE CT TM SALIVADIRECT TM IVD For Use Under Emergency Use Authorization (EUA) Only For individuals 18 years or older THIS GUIDE IS DESIGNED TO HELP YOU COMPLETE THE TEMPUS I Phenotypic Attributes and Clinical Information (see below for details) Please include a clinical history or progress notes and pathology report, or complete this section SUPPLEMENTAL INFORMATION IS REQUIRED FOR ALL ORDERS OF XG Tempus Labs, Inc. | 600 West Chicago Avenue, Chicago, IL 60654 | Phone: 800.739.4137 | Fax: 800.893.0276 | Tempus.com | support@tempus.com TEMPUS-FormXGSupp_031721ONCOLOGY - TEMPUS
How to order the Tempus sequencing test. We work directly with oncologists and pathologists to obtain normal and tumor samples. Once a physician and patient determine that Tempus testing is the right next step, the test can be ordered by the physician. Our kits include everything needed for specimen collection, including easy-to-followCOVID-19 FAQ
For patients with health insurance, Tempus bills insurers $120 for the test. Most insurers have waived patient responsibility and copays for COVID-19 diagnostic testing. For those without insurance, testing is available and covered as part of the U.S. COVID-19 Uninsured Program. More information on this program can be found here.OUR TEAM - TEMPUS
We are a team with a singular shared goal: to improve patient outcomes. We are the collective of our combined knowledge base. Our team has a breadth of expertise, and together, we attack cancer from every direction. "If you want to go fast, go alone; if you want to go far, go together." Join our team. TEMPUS AND YALE ANNOUNCE RESEARCH COLLABORATION TO Tempus, a leader in artificial intelligence and precision medicine, and the Yale School of Public Health announced a research collaboration to accelerate the development of COVID-19 diagnostic tests in the U.S. This partnership will leverage SalivaDirectTM, a saliva-based laboratory diagnostic test that has been developed by researchers at Yale. Tempus and Yale will further develop Continued TEMPUS UNVEILS TEMPUS XT, 595 GENE PANEL AIMED AT Tempus today announced the launch of its new comprehensive genomic sequencing panel, Tempus xT, which analyzes 595 genes relevant to the diagnosis, prognosis and therapeutic targeting of cancer. The panel will sequence a patient’s tumor DNA and RNA, as well as a matched normal blood or saliva to help ordering clinicians determine the targeted therapies Continued TEMPUS ANNOUNCES SEQUENCING AND COMPUTATIONAL BIOLOGY Tempus, a leader in artificial intelligence and precision medicine, today announced a collaboration with Kronos Bio, Inc., to perform sequencing analysis for patients enrolled in Kronos Bio’s Phase 1/2 clinical trial of KB-0742, the company’s investigational CDK9 inhibitor. Tempus will use its xT broad-panel genomic assay to provide retrospective sequencing and analytics for samples TEMPUS TECH SPOTLIGHT THE TEMPUS HRD TEST from a variant assessment of 16 other HR-related genes (18 total) conducted as part of the xT testing. For breast, ovarian, and pancreatic samples, the Tempus HRD test REAL-WORLD EVIDENCE OF DIAGNOSTIC TESTING AND TREATMENT Clinical Breast Cancer, Tempus-authored — Objective/Background We performed a retrospective analysis of longitudinal real-world data (RWD) from patients with breast cancer to replicate results from clinical studies and demonstrate the feasibility of generating real-world evidence. We also assessed the value of transcriptome profiling as a complementary tool for determining molecular THIS GUIDE IS DESIGNED TO HELP YOU COMPLETE THE TEMPUS I Phenotypic Attributes and Clinical Information (see below for details) Please include a clinical history or progress notes and pathology report, or complete this section CVS HEALTH LAUNCHES TRANSFORM ONCOLOGY CARE™ PROGRAM TO CVS Health (NYSE: CVS) today announced Transform Oncology Care™, anchored on a first-of-its-kind precision medicine strategy for payors. The program uses genomic testing results at the point-of-prescribing to help patients start on the best treatment, faster and in addition, matches eligible patients to clinical trials. Transform Oncology Care also uses the Company’s local footprint and TEMPUS - DATA-DRIVEN PRECISION MEDICINEPATIENTSCONTACT USAPPLICATIONSONCOLOGYNEUROLOGY & PSYCHIATRYRESEARCH Tempus is making precision medicine a reality through the power and promise of data and artificial intelligence. With the world’s largest library of clinical and molecular data, and an operating system to make that data accessible and useful, we enable physicians to make real-time, data-driven decisions to deliver personalizedpatient care
ONCOLOGY PATIENTS
Your cancer is unique. Your treatment should be, too. At Tempus, we offer comprehensive genomic testing (DNA, RNA, etc). These next-generation sequencing tests can be performed to identify specific alterations that may drive the behavior of your cancer.ONCOLOGY - TEMPUS
How to order the Tempus sequencing test. We work directly with oncologists and pathologists to obtain normal and tumor samples. Once a physician and patient determine that Tempus testing is the right next step, the test can be ordered by the physician. Our kits include everything needed for specimen collection, including easy-to-follow CLINICAL TRIAL MATCHING THE TIME TRIAL® NETWORK Accessing the right clinical trial for the right patient at the right time. The TIME Trial Program is a just-in-time network of providers to support rapid patient identification, site activation, and enrollment of select clinicaltrials.
TEMPUS PATIENT ACCESS PROGRAM Tempus Patient Access Program | Financial Assistance TEMPUS TECH SPOTLIGHT THE TEMPUS HRD TEST from a variant assessment of 16 other HR-related genes (18 total) conducted as part of the xT testing. For breast, ovarian, and pancreatic samples, the Tempus HRD testSALIVADIRECT
SALIVADIRECT TM AT-HOME COLLECTION KIT Funnel Collection SALIVADIRE CT TM SALIVADIRECT TM IVD For Use Under Emergency Use Authorization (EUA) Only For individuals 18 years or older REAL-WORLD EVIDENCE OF DIAGNOSTIC TESTING AND TREATMENT Clinical Breast Cancer, Tempus-authored — Objective/Background We performed a retrospective analysis of longitudinal real-world data (RWD) from patients with breast cancer to replicate results from clinical studies and demonstrate the feasibility of generating real-world evidence. We also assessed the value of transcriptome profiling as a complementary tool for determining molecularXF GENE PANEL
xFGeneList_092120 600 West Chicago Ave, Suite 510, Chicago, IL 60654 | TEMPUS.COM ALK BRAF FGFR2 FGFR3 NTRK1 RET ROS1 CCNE1 CD274 (PD-L1) EGFR ERBB2 (HER2) MET MYC BRCA1 BRCA2 A non-invasive, liquid biopsy panel of 105 genes focused on oncogenic and resistance mutations in SUPPLEMENTAL INFORMATION IS REQUIRED FOR ALL ORDERS OF XG Tempus Labs, Inc. | 600 West Chicago Avenue, Chicago, IL 60654 | Phone: 800.739.4137 | Fax: 800.893.0276 | Tempus.com | support@tempus.com TEMPUS-FormXGSupp_031721 TEMPUS - DATA-DRIVEN PRECISION MEDICINEPATIENTSCONTACT USAPPLICATIONSONCOLOGYNEUROLOGY & PSYCHIATRYRESEARCH Tempus is making precision medicine a reality through the power and promise of data and artificial intelligence. With the world’s largest library of clinical and molecular data, and an operating system to make that data accessible and useful, we enable physicians to make real-time, data-driven decisions to deliver personalizedpatient care
ONCOLOGY PATIENTS
Your cancer is unique. Your treatment should be, too. At Tempus, we offer comprehensive genomic testing (DNA, RNA, etc). These next-generation sequencing tests can be performed to identify specific alterations that may drive the behavior of your cancer.ONCOLOGY - TEMPUS
How to order the Tempus sequencing test. We work directly with oncologists and pathologists to obtain normal and tumor samples. Once a physician and patient determine that Tempus testing is the right next step, the test can be ordered by the physician. Our kits include everything needed for specimen collection, including easy-to-follow CLINICAL TRIAL MATCHING THE TIME TRIAL® NETWORK Accessing the right clinical trial for the right patient at the right time. The TIME Trial Program is a just-in-time network of providers to support rapid patient identification, site activation, and enrollment of select clinicaltrials.
TEMPUS PATIENT ACCESS PROGRAM Tempus Patient Access Program | Financial Assistance TEMPUS TECH SPOTLIGHT THE TEMPUS HRD TEST from a variant assessment of 16 other HR-related genes (18 total) conducted as part of the xT testing. For breast, ovarian, and pancreatic samples, the Tempus HRD testSALIVADIRECT
SALIVADIRECT TM AT-HOME COLLECTION KIT Funnel Collection SALIVADIRE CT TM SALIVADIRECT TM IVD For Use Under Emergency Use Authorization (EUA) Only For individuals 18 years or older REAL-WORLD EVIDENCE OF DIAGNOSTIC TESTING AND TREATMENT Clinical Breast Cancer, Tempus-authored — Objective/Background We performed a retrospective analysis of longitudinal real-world data (RWD) from patients with breast cancer to replicate results from clinical studies and demonstrate the feasibility of generating real-world evidence. We also assessed the value of transcriptome profiling as a complementary tool for determining molecularXF GENE PANEL
xFGeneList_092120 600 West Chicago Ave, Suite 510, Chicago, IL 60654 | TEMPUS.COM ALK BRAF FGFR2 FGFR3 NTRK1 RET ROS1 CCNE1 CD274 (PD-L1) EGFR ERBB2 (HER2) MET MYC BRCA1 BRCA2 A non-invasive, liquid biopsy panel of 105 genes focused on oncogenic and resistance mutations in SUPPLEMENTAL INFORMATION IS REQUIRED FOR ALL ORDERS OF XG Tempus Labs, Inc. | 600 West Chicago Avenue, Chicago, IL 60654 | Phone: 800.739.4137 | Fax: 800.893.0276 | Tempus.com | support@tempus.com TEMPUS-FormXGSupp_031721ONCOLOGY - TEMPUS
How to order the Tempus sequencing test. We work directly with oncologists and pathologists to obtain normal and tumor samples. Once a physician and patient determine that Tempus testing is the right next step, the test can be ordered by the physician. Our kits include everything needed for specimen collection, including easy-to-followCOVID-19 FAQ
For patients with health insurance, Tempus bills insurers $120 for the test. Most insurers have waived patient responsibility and copays for COVID-19 diagnostic testing. For those without insurance, testing is available and covered as part of the U.S. COVID-19 Uninsured Program. More information on this program can be found here. TEMPUS UNVEILS TEMPUS XT, 595 GENE PANEL AIMED AT Tempus today announced the launch of its new comprehensive genomic sequencing panel, Tempus xT, which analyzes 595 genes relevant to the diagnosis, prognosis and therapeutic targeting of cancer. The panel will sequence a patient’s tumor DNA and RNA, as well as a matched normal blood or saliva to help ordering clinicians determine the targeted therapies Continued TEMPUS AND YALE ANNOUNCE RESEARCH COLLABORATION TO Tempus, a leader in artificial intelligence and precision medicine, and the Yale School of Public Health announced a research collaboration to accelerate the development of COVID-19 diagnostic tests in the U.S. This partnership will leverage SalivaDirectTM, a saliva-based laboratory diagnostic test that has been developed by researchers at Yale. Tempus and Yale will further develop Continued TEMPUS ANNOUNCES SEQUENCING AND COMPUTATIONAL BIOLOGY Tempus, a leader in artificial intelligence and precision medicine, today announced a collaboration with Kronos Bio, Inc., to perform sequencing analysis for patients enrolled in Kronos Bio’s Phase 1/2 clinical trial of KB-0742, the company’s investigational CDK9 inhibitor. Tempus will use its xT broad-panel genomic assay to provide retrospective sequencing and analytics for samplesNEURO & PSYCH
To find out immediately if you qualify for financial assistance, you can apply here. If you have questions related to our billing process or financial assistance program, please contact us 800-739-4137 orbilling@tempus.com.
MARC YOSKOWITZ
Marc Yoskowitz Marc Yoskowitz serves as EVP and Chief Strategy Officer, Life Sciences at Tempus. Prior to Tempus, Yoskowitz was Chief Business Officer, Pfizer Essential Health, leading a range of corporate initiatives and businesses within the Pfizer portfolio. Prior to Pfizer, he served as SVP, Strategy and Corporate Development at Hospira, where he led the Continued TEMPUS TIME TRIAL™ PROGRAM REACHES CRITICAL SCALE AND Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, has reached a milestone in fully enrolling 2,500 oncologists into its Tempus Integrated Molecular Evaluation (TIME) Trial™ Program that seeks to rapidly match patients largely in the community setting to targeted clinical trials. To date, Tempus has signed XT GENE PANEL, FOR USE WITH XT 648 gene panel focused on actionable mutations by DNA sequencing • Specimen: tumor and matched normal (peripheral blood or saliva) • Single nucleotide variants, indels, and copy number variants are detected in 648 genes CVS HEALTH LAUNCHES TRANSFORM ONCOLOGY CARE™ PROGRAM TO CVS Health (NYSE: CVS) today announced Transform Oncology Care™, anchored on a first-of-its-kind precision medicine strategy for payors. The program uses genomic testing results at the point-of-prescribing to help patients start on the best treatment, faster and in addition, matches eligible patients to clinical trials. Transform Oncology Care also uses the Company’s local footprint and TEMPUS - DATA-DRIVEN PRECISION MEDICINEPATIENTSCONTACT USAPPLICATIONSONCOLOGYNEUROLOGY & PSYCHIATRYRESEARCH Tempus is making precision medicine a reality through the power and promise of data and artificial intelligence. With the world’s largest library of clinical and molecular data, and an operating system to make that data accessible and useful, we enable physicians to make real-time, data-driven decisions to deliver personalizedpatient care
ONCOLOGY PATIENTS
Your cancer is unique. Your treatment should be, too. At Tempus, we offer comprehensive genomic testing (DNA, RNA, etc). These next-generation sequencing tests can be performed to identify specific alterations that may drive the behavior of your cancer.ONCOLOGY - TEMPUS
How to order the Tempus sequencing test. We work directly with oncologists and pathologists to obtain normal and tumor samples. Once a physician and patient determine that Tempus testing is the right next step, the test can be ordered by the physician. Our kits include everything needed for specimen collection, including easy-to-followOUR TEAM - TEMPUS
We are a team with a singular shared goal: to improve patient outcomes. We are the collective of our combined knowledge base. Our team has a breadth of expertise, and together, we attack cancer from every direction. "If you want to go fast, go alone; if you want to go far, go together." Join our team. CLINICAL TRIAL MATCHING THE TIME TRIAL® NETWORK Accessing the right clinical trial for the right patient at the right time. The TIME Trial Program is a just-in-time network of providers to support rapid patient identification, site activation, and enrollment of select clinicaltrials.
TEMPUS PATIENT ACCESS PROGRAM Tempus Patient Access Program | Financial Assistance TEMPUS UNVEILS TEMPUS XT, 595 GENE PANEL AIMED ATTEMPUS XT PANEL Tempus today announced the launch of its new comprehensive genomic sequencing panel, Tempus xT, which analyzes 595 genes relevant to the diagnosis, prognosis and therapeutic targeting of cancer. The panel will sequence a patient’s tumor DNA and RNA, as well as a matched normal blood or saliva to help ordering clinicians determine the targeted therapies ContinuedSALIVADIRECT
SALIVADIRECT TM AT-HOME COLLECTION KIT Funnel Collection SALIVADIRE CT TM SALIVADIRECT TM IVD For Use Under Emergency Use Authorization (EUA) Only For individuals 18 years or olderMARC YOSKOWITZ
Marc Yoskowitz Marc Yoskowitz serves as EVP and Chief Strategy Officer, Life Sciences at Tempus. Prior to Tempus, Yoskowitz was Chief Business Officer, Pfizer Essential Health, leading a range of corporate initiatives and businesses within the Pfizer portfolio. Prior to Pfizer, he served as SVP, Strategy and Corporate Development at Hospira, where he led the Continued SUPPLEMENTAL INFORMATION IS REQUIRED FOR ALL ORDERS OF XG Tempus Labs, Inc. | 600 West Chicago Avenue, Chicago, IL 60654 | Phone: 800.739.4137 | Fax: 800.893.0276 | Tempus.com | support@tempus.com TEMPUS-FormXGSupp_031721 TEMPUS - DATA-DRIVEN PRECISION MEDICINEPATIENTSCONTACT USAPPLICATIONSONCOLOGYNEUROLOGY & PSYCHIATRYRESEARCH Tempus is making precision medicine a reality through the power and promise of data and artificial intelligence. With the world’s largest library of clinical and molecular data, and an operating system to make that data accessible and useful, we enable physicians to make real-time, data-driven decisions to deliver personalizedpatient care
ONCOLOGY PATIENTS
Your cancer is unique. Your treatment should be, too. At Tempus, we offer comprehensive genomic testing (DNA, RNA, etc). These next-generation sequencing tests can be performed to identify specific alterations that may drive the behavior of your cancer.ONCOLOGY - TEMPUS
How to order the Tempus sequencing test. We work directly with oncologists and pathologists to obtain normal and tumor samples. Once a physician and patient determine that Tempus testing is the right next step, the test can be ordered by the physician. Our kits include everything needed for specimen collection, including easy-to-followOUR TEAM - TEMPUS
We are a team with a singular shared goal: to improve patient outcomes. We are the collective of our combined knowledge base. Our team has a breadth of expertise, and together, we attack cancer from every direction. "If you want to go fast, go alone; if you want to go far, go together." Join our team. CLINICAL TRIAL MATCHING THE TIME TRIAL® NETWORK Accessing the right clinical trial for the right patient at the right time. The TIME Trial Program is a just-in-time network of providers to support rapid patient identification, site activation, and enrollment of select clinicaltrials.
TEMPUS PATIENT ACCESS PROGRAM Tempus Patient Access Program | Financial Assistance TEMPUS UNVEILS TEMPUS XT, 595 GENE PANEL AIMED ATTEMPUS XT PANEL Tempus today announced the launch of its new comprehensive genomic sequencing panel, Tempus xT, which analyzes 595 genes relevant to the diagnosis, prognosis and therapeutic targeting of cancer. The panel will sequence a patient’s tumor DNA and RNA, as well as a matched normal blood or saliva to help ordering clinicians determine the targeted therapies ContinuedSALIVADIRECT
SALIVADIRECT TM AT-HOME COLLECTION KIT Funnel Collection SALIVADIRE CT TM SALIVADIRECT TM IVD For Use Under Emergency Use Authorization (EUA) Only For individuals 18 years or olderMARC YOSKOWITZ
Marc Yoskowitz Marc Yoskowitz serves as EVP and Chief Strategy Officer, Life Sciences at Tempus. Prior to Tempus, Yoskowitz was Chief Business Officer, Pfizer Essential Health, leading a range of corporate initiatives and businesses within the Pfizer portfolio. Prior to Pfizer, he served as SVP, Strategy and Corporate Development at Hospira, where he led the Continued SUPPLEMENTAL INFORMATION IS REQUIRED FOR ALL ORDERS OF XG Tempus Labs, Inc. | 600 West Chicago Avenue, Chicago, IL 60654 | Phone: 800.739.4137 | Fax: 800.893.0276 | Tempus.com | support@tempus.com TEMPUS-FormXGSupp_031721OUR TEAM - TEMPUS
We are a team with a singular shared goal: to improve patient outcomes. We are the collective of our combined knowledge base. Our team has a breadth of expertise, and together, we attack cancer from every direction. "If you want to go fast, go alone; if you want to go far, go together." Join our team.PRODUCTS & SERVICES
From genomic sequencing, to clinical data structuring, and image recognition, Tempus has developed tools to collect, cleanse, and analyze data to find better solutions. Cancer is a computational problem and we can solve computational problems. We just need data. COMPANION DIAGNOSTICS Companion Diagnostics for Targeted Therapies. Building a partnership from development through commercialization. Tempus offers companion diagnostic development across our portfolio of assays, leveraging a broad-panel, universal platform used by thousands of oncologistsglobally.
DATA LICENSING
DATA LICENSING. Uncover new insights with datasets designed for the precision medicine era.. Tempus has assembled the largest multi-modal real-world dataset to empower AI-driven research to improve patient care. Tempus analyzes nearly 1/3 of all U.S. cancer patients and a growing percentage of depression patients. TEMPUS TECH SPOTLIGHT THE TEMPUS HRD TEST from a variant assessment of 16 other HR-related genes (18 total) conducted as part of the xT testing. For breast, ovarian, and pancreatic samples, the Tempus HRD testONCOLOGY FAQ
A test can be ordered by faxing a completed requisition form to us at 800.893.0276. What type of sequencing does Tempus perform? Our labs sequence both DNA and RNA from tumor samples as well as matched DNA from normal samples. Sequencing options include a targeted panel of 648 genes (at 500x coverage), whole exome (at 150x coverage), andwhole
XF GENE PANEL
xFGeneList_092120 600 West Chicago Ave, Suite 510, Chicago, IL 60654 | TEMPUS.COM ALK BRAF FGFR2 FGFR3 NTRK1 RET ROS1 CCNE1 CD274 (PD-L1) EGFR ERBB2 (HER2) MET MYC BRCA1 BRCA2 A non-invasive, liquid biopsy panel of 105 genes focused on oncogenic and resistance mutations inMARC YOSKOWITZ
Marc Yoskowitz Marc Yoskowitz serves as EVP and Chief Strategy Officer, Life Sciences at Tempus. Prior to Tempus, Yoskowitz was Chief Business Officer, Pfizer Essential Health, leading a range of corporate initiatives and businesses within the Pfizer portfolio. Prior to Pfizer, he served as SVP, Strategy and Corporate Development at Hospira, where he led the ContinuedRYAN FUKUSHIMA
Ryan Fukushima Ryan Fukushima serves as Chief Operating Officer at Tempus. Prior to Tempus, Fukushima was an Entrepreneur-in-Residence and Vice President at Lightbank, focusing investments on enterprise software and launching businesses. Earlier he was at Hyde Park Venture Partners, where he concentrated on enterprise investments in the Midwest. Before landing in Chicago, Fukushima worked CVS HEALTH LAUNCHES TRANSFORM ONCOLOGY CARE™ PROGRAM TO CVS Health (NYSE: CVS) today announced Transform Oncology Care™, anchored on a first-of-its-kind precision medicine strategy for payors. The program uses genomic testing results at the point-of-prescribing to help patients start on the best treatment, faster and in addition, matches eligible patients to clinical trials.Tempus
Menu
Tempus
* Home
* Physician Login Opens a new window* Patients
* Contact Us
* Applications
* Oncology
* Neurology & Psychiatry* Research
* Life Sciences
* Infectious Disease * Products & Services* Genomic Profiling
* Data Licensing
* Clinical Trial Matching * Companion Diagnostics * Additional Testing* Tempus ONE
* About Us
* Our Team
* Careers
* Culture
* News
* Publications
4.0 Home
ACCESS REAL-WORLD DATA FROM TEMPUS' GROWING ONCOLOGY DATASET.* 3
* ,
* 7
* 0
* 8
* ,
* 6
* 8
* 1
TEMPUS HAS DATA FOR OVER 3.5 MILLION PATIENT RECORDS TODAY (AND COUNTING). LEARN MORE ABOUT ACCESSING THIS DATA.DATA-DRIVEN
PRECISION MEDICINE
TEMPUS IS MAKING PRECISION MEDICINE A REALITY THROUGH THE POWER AND PROMISE OF DATA AND ARTIFICIAL INTELLIGENCE. With the world’s largest library of clinical and molecular data, and an operating system to make that data accessible and useful, we enable physicians to make real-time, data-driven decisions to deliver personalized patient care, and in parallel, facilitate discovery, development, and delivery of optimized therapeutic options for patients through distinctive solution sets.Open video in popup
WITH THE RIGHT DATA, WE CAN ACCELERATE CANCER RESEARCH. We can usher in an era of true precision medicine and revolutionize how data is used to personalize and optimize treatments. We can harness the power of data to redefine cancer care.IT'S ABOUT TIME.
What we do
W
h
a
t
w
e
d
o
GENERATE GENOMIC RESULTS Our genomic tests analyze DNA, RNA, and proteomic data to understand a patient's tumor at the molecular level so we can identify treatment options tailored to each and every patient. TRANSFORM UNSTRUCTURED DATA We ingest and organize clinical notes, lab reports, pathology images, and radiology scans to capture phenotypic, therapeutic, and outcomes data to understand the clinical context for each patient case. DELIVER ACTIONABLE INSIGHTS Our platform analyzes thousands of clinical and molecular data points, connecting physicians with up-to-date treatment options and relevant insights for patients based on their unique molecular profile and our advanced analytics and machine-learning algorithms. WELCOME TO THE FUTURE OF DATA-DRIVEN HEALTHCARE.Contact Us
* Home
* Physician Login Opens a new window* Patients
* Contact Us
* Applications
* Oncology
* Neurology & Psychiatry* Research
* Life Sciences
* Infectious Disease * Products & Services* Genomic Profiling
* Data Licensing
* Clinical Trial Matching * Companion Diagnostics * Additional Testing* Tempus ONE
* About Us
* Our Team
* Careers
* Culture
* News
* Publications
* FAQ
* Media Kit
* Resources
* Facebook Opens a new window * Twitter Opens a new window * Linkedin Opens a new window * YouTube Opens a new window All Content Copyright 2021 | Privacy Policy | Notice of PrivacyPractices
|
Terms of Use
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0